Verrica Pharmaceuticals presents new data on VP-315 from Phase 2 trial

Verrica Pharmaceuticals (VRCA) announced the presentation of new data from its Phase 2 study evaluating VP-315, a novel oncolytic peptide immunotherapy, at the Society for Immunotherapy of Cancer, SITC, 40th Annual Meeting which took place November 5-9, 2025, in National Harbor, Maryland. Data were featured in both a poster presentation and an oral presentation highlighting the local immune activation and clinical efficacy of VP-315 in patients with basal cell carcinoma. Key highlights: Exploratory Phase 2 analysis shows Verrica’s novel oncolytic peptide, VP-315, reprograms the tumor microenvironment, increasing cytotoxic T-cell infiltration and reducing immunosuppressive T-regulatory cells; Findings provide mechanistic immunologic support for clinical efficacy previously reported, including 97% calculated objective response rate and 51% complete histologic clearance rate; Coupled with VP-315’s previously reported safety profile, these results highlight VP-315’s potential as a first-in-class, non-surgical immunotherapeutic option for patients with basal cell carcinoma